Management of Heart Failure with Left Bundle Branch Block

Beta-Blocker Therapy

The American College of Cardiology recommends three beta-blockers, including bisoprolol, carvedilol, and sustained-release metoprolol succinate, for mortality benefits in heart failure with reduced ejection fraction (HFrEF), with a Class I, Level of Evidence A recommendation for all patients with current or prior symptoms of HFrEF, regardless of conduction abnormalities 1, 3
Beta-blockers should be initiated at low doses and gradually titrated to target doses or maximally tolerated doses, with the target dose for metoprolol succinate in HFrEF being 200 mg once daily 2, 3
The American Heart Association and European Heart Society guidelines do not list LBBB as a contraindication to beta-blocker therapy, and recommend achieving at least 50% of the target dose when possible 1, 4, 5

The American College of Cardiology recommends monitoring heart rate and blood pressure closely during initiation and titration of metoprolol in LBBB patients, and considering cardiac resynchronization therapy (CRT) if medical therapy optimization does not improve symptoms 6
For patients with LBBB and atrial fibrillation, beta-blockers remain the most effective drug class for rate control, and carvedilol or bisoprolol are appropriate alternatives for patients who cannot tolerate metoprolol 2, 6

The American College of Cardiology recommends starting metoprolol succinate at a low dose (12.5-25 mg daily) in patients with LBBB, and titrating gradually every 2 weeks as tolerated toward the target dose of 200 mg daily 2, 3
Beta-blocker therapy should be continued long-term even if symptoms improve, and patients with LBBB-associated cardiomyopathy who do not respond adequately to medical therapy including beta-blockers should be considered for referral for evaluation for cardiac resynchronization therapy 2